Creatine and Brain Health: What the Cognitive Evidence Supports

Creatine spent three decades as a sports supplement before anyone paid serious attention to what it does above the neck. That has changed quickly, and the brain research is now among the most active areas in the field.

It is also the area where the gap between the headlines and the evidence is widest. The underlying mechanism is genuinely well established; the clinical claims built on top of it range from reasonably supported to frankly speculative. This guide sorts them.

Key Takeaways

• The mechanism is not in doubt. The brain runs a phosphocreatine energy buffer just as muscle does, and it consumes a large share of the body's energy budget.
• Effects concentrate under stress. The clearest results appear when the brain is energetically strained — sleep deprivation, ageing, low baseline stores — not in rested young adults.
• Brain uptake is slower and harder than muscle uptake, which is why cognitive protocols often use higher doses than the standard 5 g.
• Evidence quality varies enormously by claim. Sleep deprivation and ageing have real trial data. Depression has one small randomised trial of creatine added to an antidepressant. Brain injury and Alzheimer's rest on pilot studies.

Why the Brain Cares About Creatine

Your brain is roughly 2% of body weight and consumes something like 20% of your energy at rest. It sustains that demand through ATP, and ATP is not stored in quantity — it is continuously regenerated.

This is exactly the job the phosphocreatine system¹ does. Phosphocreatine donates a phosphate group to ADP to regenerate ATP rapidly, acting as a short-term energy buffer for sudden demand. Muscle uses it during a sprint. Neurons use it constantly.

Because of this, brain creatine content correlates with the tissue's capacity to buffer energetic stress. Where that capacity is already sufficient, adding more should do little. Where it is strained, adding more has somewhere useful to go. That single idea predicts the shape of nearly all the findings below.

Where the Evidence Is Strongest

Sleep deprivation

The clearest demonstration of the stress principle. A 2026 crossover trial gave a single 0.2 g/kg dose — around 14 g for a 70 kg adult — to participants undergoing 21 hours of sleep deprivation. It mitigated deterioration in logical and numerical reasoning, language processing speed, and vigilance, with improvements up to 12% against placebo.

Two details matter. The effect was smaller than that seen at a higher 0.35 g/kg dose in the same group's earlier work, suggesting dose dependence. And subjective fatigue and sleepiness increased normally — participants felt no less tired, they simply performed better. Our full write-up is in Can a Single Dose of Creatine Protect Your Brain During Sleep Deprivation?

This remains a small acute trial rather than a settled result. But it is a direct test of the mechanism, and it behaved as the mechanism predicts.

Ageing and cognition in older adults

Systematic reviews of randomised trials have found modest cognitive benefits, most consistently for memory. A 2018 review of six trials found evidence that short-term memory and intelligence/reasoning may improve, with conflicting results in other domains, no change in young people, and hints of benefit in ageing and stressed individuals. A 2024 meta-analysis of sixteen trials rated the evidence for memory as moderate and for attention and processing speed as low certainty. A 12-week trial in sedentary adults aged 45 to 65 found improvements across several memory tests — though the authors themselves categorised the cognitive outcomes as exploratory, which is an important qualification. That study is covered in Creatine for Middle-Aged and Older Adults.

The related "muscle-brain axis" work suggests creatine combined with resistance training may act on both tissues at once, with exercise-released myokines² contributing alongside the direct energetic effect. See Creatine Supplementation and the Muscle-Brain Axis in Aging — noting that the underlying paper is a narrative review³ by a single author, not a trial.

People with low baseline stores

The same pattern again: cognitive effects appear most consistently in people who start with less creatine — most notably vegetarians and vegans. Rested, well-fed young omnivores are the group in which studies most often find nothing, which is what you would expect if the brain's buffer is already adequately stocked.

Where the Evidence Is Preliminary

This is where care is required, because these are the applications generating the most enthusiastic coverage.

Depression. There is some trial evidence here, but only as an add-on. In a double-blind randomised trial, 52 women with major depressive disorder took the antidepressant escitalopram with either 5 g/day of creatine or placebo; the creatine group improved more on the Hamilton depression scale from week 2 through week 8. That is a real result, but it is one small trial, in women only, with creatine added to an antidepressant rather than used alone. Separately, a 2026 integrative review proposed combining creatine, branched-chain amino acids and exercise to reprogram brain bioenergetics in depression — a mechanistically coherent framework built on real disruptions in cerebral energy metabolism, but a theoretical synthesis rather than a trial. We cover it in Reprogramming Brain Bioenergetics in Depression. Creatine is not a standalone treatment for depression, and anyone managing a mood disorder should be discussing adjuncts with their clinician.

Traumatic brain injury. Brain injury produces a well-documented metabolic crisis in which energy demand outstrips supply, and supporting the phosphocreatine system during that window is a reasonable idea. The human evidence is a single open-label study of 39 children and adolescents with traumatic brain injury, reported in two papers. These were serious injuries — outcomes included time on a ventilator and in intensive care — so the results say nothing direct about concussion, or about adults, and they have not been replicated. This is a plausible hypothesis, not established care, and it is emphatically not an emergency protocol — a suspected head injury needs medical assessment.

Alzheimer's disease. The first clinical trial in patients was CABA, a single-arm pilot trial⁴ in which 20 patients took 20 g/day for eight weeks. Nineteen met the compliance target, brain creatine rose by 11%, and several cognitive scores improved. With no control group, those cognitive changes cannot be separated from practice effects or expectation, and the authors present them as preliminary evidence for future trials. Pilot studies establish that a larger trial can be run. They do not establish benefit.

The honest framing across all three: the mechanism is shared, and the outcomes are not established — one small positive add-on trial in depression, and pilot data elsewhere. These are areas of active investigation, and describing them otherwise would misrepresent the literature.

Dosing for Cognitive Effects

Brain protocols often use more than the standard 5 g/day, and there is a reason.

Creatine crosses the blood-brain barrier⁵ more slowly and less readily than it enters muscle, mediated by a transporter that limits uptake. Brain creatine stores respond more sluggishly to supplementation than muscle stores do — so a dose that saturates muscle comfortably may move brain concentrations only slightly.

This is why the cognitive literature tends toward higher doses — the sleep deprivation work used 0.2 to 0.35 g/kg, which for a 70 kg adult is roughly 14 to 25 g — and why acute studies frequently use a single large dose rather than a maintenance schedule.

Two cautions. Doses in that range carry a materially higher risk of gastrointestinal distress; see Creatine Side Effects and Safety. And these are research protocols run for defined periods under supervision, not long-term regimens with established safety data at that intake. The CreatineIQ brain health calculator works from the published protocols, but the ceiling of what is known is genuinely lower here than on the muscle side.

References

1. Avgerinos KI, Spyrou N, Bougioukas KI, Kapogiannis D. Effects of creatine supplementation on cognitive function of healthy individuals: A systematic review of randomized controlled trials. Experimental Gerontology (2018). DOI: 10.1016/j.exger.2018.04.013
2. Xu C, Bi S, Zhang W, Luo L. The effects of creatine supplementation on cognitive function in adults: a systematic review and meta-analysis. Frontiers in Nutrition (2024). DOI: 10.3389/fnut.2024.1424972
3. Roschel H, Gualano B, Ostojic SM, Rawson ES. Creatine Supplementation and Brain Health. Nutrients (2021). DOI: 10.3390/nu13020586
4. Candow DG, Forbes SC, Ostojic SM, et al. "Heads Up" for Creatine Supplementation and its Potential Applications for Brain Health and Function. Sports Medicine (2023). DOI: 10.1007/s40279-023-01870-9
5. Taylor MK, Burns JM, Choi I-Y, et al. Protocol for a single-arm, pilot trial of creatine monohydrate supplementation in patients with Alzheimer's disease. Pilot and Feasibility Studies (2024). DOI: 10.1186/s40814-024-01469-5
6. Smith AN, Choi IY, Lee P, et al. Creatine monohydrate pilot in Alzheimer's: Feasibility, brain creatine, and cognition. Alzheimer's & Dementia: Translational Research & Clinical Interventions (2025). PubMed 40395689 · DOI: 10.1002/trc2.70101
7. Lyoo IK, Yoon S, Kim TS, et al. A randomized, double-blind placebo-controlled trial of oral creatine monohydrate augmentation for enhanced response to a selective serotonin reuptake inhibitor in women with major depressive disorder. American Journal of Psychiatry (2012). PubMed 22864465 · DOI: 10.1176/appi.ajp.2012.12010009
8. Sakellaris G, Kotsiou M, Tamiolaki M, et al. Prevention of complications related to traumatic brain injury in children and adolescents with creatine administration: an open label randomized pilot study. Journal of Trauma (2006). PubMed 16917445 · DOI: 10.1097/01.ta.0000230269.46108.d5
9. Sakellaris G, Nasis G, Kotsiou M, et al. Prevention of traumatic headache, dizziness and fatigue with creatine administration. A pilot study. Acta Paediatrica (2008). PubMed 18053002 · DOI: 10.1111/j.1651-2227.2007.00529.x

Glossary

1. Phosphocreatine system: The mechanism by which phosphocreatine donates a phosphate group to ADP to regenerate ATP, buffering short-term energy demand in muscle and brain. ↩

2. Myokines: Signalling molecules released by contracting skeletal muscle, some of which act on the brain to support neuroplasticity. ↩

3. Narrative review: A survey of literature written without the predefined search and inclusion criteria of a systematic review, and correspondingly more open to selection bias. ↩

4. Single-arm pilot trial: A small study with no control group, run to establish feasibility and safety before a larger controlled trial. Not designed to demonstrate benefit. ↩

5. Blood-brain barrier: The selective barrier controlling passage of substances from blood into brain tissue. Creatine crosses it via a transporter, more slowly than it enters muscle. ↩